JPH1179981A - 消炎・沈痛貼付剤 - Google Patents
消炎・沈痛貼付剤Info
- Publication number
- JPH1179981A JPH1179981A JP9244181A JP24418197A JPH1179981A JP H1179981 A JPH1179981 A JP H1179981A JP 9244181 A JP9244181 A JP 9244181A JP 24418197 A JP24418197 A JP 24418197A JP H1179981 A JPH1179981 A JP H1179981A
- Authority
- JP
- Japan
- Prior art keywords
- metal
- pain
- inflammatory
- potential
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011505 plaster Substances 0.000 title abstract description 8
- 230000000202 analgesic effect Effects 0.000 title abstract 5
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 5
- 230000001741 anti-phlogistic effect Effects 0.000 title abstract 5
- 239000002184 metal Substances 0.000 claims abstract description 36
- 229910052751 metal Inorganic materials 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000004615 ingredient Substances 0.000 claims abstract description 11
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 8
- 239000010419 fine particle Substances 0.000 claims abstract description 7
- 229910052737 gold Inorganic materials 0.000 claims abstract description 7
- 229910052726 zirconium Inorganic materials 0.000 claims abstract description 7
- 150000004767 nitrides Chemical class 0.000 claims abstract description 6
- 229910052709 silver Inorganic materials 0.000 claims abstract description 6
- 239000000956 alloy Substances 0.000 claims abstract description 4
- 229910045601 alloy Inorganic materials 0.000 claims abstract description 4
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims abstract description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical class CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 20
- 230000003119 painkilling effect Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 3
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 3
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 2
- 229960002504 capsaicin Drugs 0.000 claims description 2
- 235000017663 capsaicin Nutrition 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 15
- 150000002739 metals Chemical class 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 239000011369 resultant mixture Substances 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 description 21
- 230000006870 function Effects 0.000 description 8
- 208000034656 Contusions Diseases 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 208000034526 bruise Diseases 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 150000001247 metal acetylides Chemical class 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical class CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 229940000033 dermatological agent Drugs 0.000 description 2
- 239000003241 dermatological agent Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001354 painful effect Effects 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- 229910001020 Au alloy Inorganic materials 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 239000003353 gold alloy Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 239000010944 silver (metal) Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9244181A JPH1179981A (ja) | 1997-09-09 | 1997-09-09 | 消炎・沈痛貼付剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9244181A JPH1179981A (ja) | 1997-09-09 | 1997-09-09 | 消炎・沈痛貼付剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH1179981A true JPH1179981A (ja) | 1999-03-23 |
| JPH1179981A5 JPH1179981A5 (enExample) | 2005-01-06 |
Family
ID=17114979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9244181A Pending JPH1179981A (ja) | 1997-09-09 | 1997-09-09 | 消炎・沈痛貼付剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH1179981A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016208556A1 (ja) * | 2015-06-22 | 2016-12-29 | プラチナブブ株式会社 | リラックス用組成物 |
-
1997
- 1997-09-09 JP JP9244181A patent/JPH1179981A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016208556A1 (ja) * | 2015-06-22 | 2016-12-29 | プラチナブブ株式会社 | リラックス用組成物 |
| JPWO2016208556A1 (ja) * | 2015-06-22 | 2018-06-07 | プラチナブブ株式会社 | リラックス用組成物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2268075C2 (ru) | Устройство для электрокинетической доставки | |
| JP4090072B2 (ja) | 経皮電気的移送式作用剤投与を促進するための組成物と方法 | |
| Khan et al. | Iontophoretic drug delivery: history and applications | |
| US20010044592A1 (en) | Methods for delivering agents using alternating current | |
| US20220142953A1 (en) | Lidocaine patch and methods of use thereof | |
| EP2012871A2 (en) | Transdermal methods and systems for the delivery of anti-migraine compounds | |
| US4755384A (en) | Externally applied antispasmatic products | |
| US6375990B1 (en) | Method and devices for transdermal delivery of lithium | |
| US11052240B2 (en) | Electro kinetic transdermal and trans mucosal delivery accelerator device | |
| Banga et al. | A review of patent literature for iontophoretic delivery and devices | |
| JPH1179981A (ja) | 消炎・沈痛貼付剤 | |
| KR0146694B1 (ko) | 다기능 치료 장치 | |
| Nayak et al. | Iontophoretic drug delivery systems | |
| JPH11146917A (ja) | 貼付剤 | |
| CN106178253A (zh) | 一种基于疏密波的穴位电刺激方法及装置 | |
| JPH1179981A5 (enExample) | ||
| Gazelius | Iontophoresis-theory | |
| CN101198373A (zh) | 直流组织治疗 | |
| Abla et al. | Iontophoresis: clinical applications and future challenges | |
| JP4171630B2 (ja) | イオン導入具 | |
| AU2006202742B2 (en) | Method and devices for transdermal delivery of lithium | |
| WO2024218387A1 (en) | Use of charged air ions in cosmetic treatments | |
| JPH10323399A (ja) | 生体機能回復用付着体 | |
| Singh et al. | Iontophoretic delivery of drugs: maximizing treatment effectiveness | |
| JPH10323400A (ja) | 生体機能回復用付着体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040206 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060725 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070220 |